0.36%
12.95%
40.00%
46.75%
49.17%
-17.65%
133.33%
AI Spotlight on CHEMM
Company Description
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer.Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension.
It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans.The company was incorporated in 1997 and is headquartered in Allerød, Denmark.
Market Data
| Last Price | 560 |
| Change Percentage | 0.36% |
| Open | 560 |
| Previous Close | 558 |
| Market Cap ( Millions) | 9745 |
| Volume | 36323 |
| Year High | 563 |
| Year Low | 281.2 |
| M A 50 | 495.24 |
| M A 200 | 402.87 |
Financial Ratios
| FCF Yield | 1.11% |
| Dividend Yield | 0.71% |
| ROE | 25.62% |
| Debt / Equity | 0.73% |
| Net Debt / EBIDTA | -163.32% |
| Price To Book | 17.24 |
| Price Earnings Ratio | 71.51 |
| Price To FCF | 90.19 |
| Price To sales | 23.89 |
| EV / EBITDA | 52.88 |
News
- Jan -10 - Upgrade of revenue and operating profit guidance
- Dec -09 - Major shareholder announcement – AIM International Mutual Funds
- Dec -09 - Major shareholder announcement – Invesco Ltd.
- Dec -03 - Upgrade of revenue and operating profit guidance
- Nov -08 - Notification of managers’ transactions
- Nov -07 - Growth in revenue and operating profit
- Oct -22 - Closing of acquisition of Ovizio Imaging Systems SA
- Oct -16 - Acquisition of Ovizio Imaging Systems SA
- Oct -16 - Upgrade of revenue and operating profit guidance
- Oct -11 - ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA
- Oct -10 - Procedure of the Annual General Meeting
- Sep -20 - ChemoMetec makes offer to buy Ovizio Imaging Systems SA
- Sep -13 - Notification of managers’ transactions
- Sep -11 - Annual Report 2023/24 - Strengthened commercial focus after challenging year
- Sep -11 - Guidance for the 2024/25 financial year
- Jul -04 - Major shareholder announcement – BlackRock, Inc.
- Jul -02 - Preliminary revenue figures for the 2023/24 financial year
- May -24 - Appointment of new CFO
- May -17 - Notification of managers’ transactions
- May -15 - Major shareholder announcement – BlackRock, Inc.
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Instruments
Expected Growth : 12 %
What the company do ?
Instruments from ChemoMetec A/S are automated cell counters and analyzers for cell culture and microbiology applications, providing accurate and efficient cell counting and analysis.
Why we expect these perspectives ?
ChemoMetec A/S's 12% growth is driven by increasing demand for automated cell counting and analysis in life sciences, expansion into emerging markets, and strategic partnerships. Additionally, the company's focus on innovation, quality, and customer satisfaction has led to market share gains and repeat business. Furthermore, the growing need for efficient and accurate cell analysis in biotechnology, pharmaceutical, and research industries also contributes to the company's growth.
Segment n°2 -> Consumables
Expected Growth : 14 %
What the company do ?
Consumables from ChemoMetec A/S are high-quality, precision-made components for cell counting and analysis, ensuring accurate and reliable results in various laboratory settings.
Why we expect these perspectives ?
Strong demand for automated cell counting and analysis in life sciences, increasing adoption of single-cell analysis in cancer research, and growing need for efficient cell culture monitoring drive Consumables growth from ChemoMetec A/S, with a 14% growth rate.
Segment n°3 -> Service
Expected Growth : 11 %
What the company do ?
ChemoMetec A/S offers a cell counting service, providing accurate and reliable cell counting and viability assessment for various cell types.
Why we expect these perspectives ?
ChemoMetec A/S's 11% growth is driven by increasing demand for automated cell counting and analysis in life science research, rising adoption of single-cell analysis in cancer research, and growing need for high-throughput screening in pharmaceutical industries, coupled with the company's expanding product portfolio and strategic partnerships.
Segment n°4 -> Other
Expected Growth : 10 %
What the company do ?
The Other from ChemoMetec A/S refers to a category of miscellaneous products not classified under their main product lines, including accessories and consumables.
Why we expect these perspectives ?
ChemoMetec A/S's 10% growth in 'Other' segment is driven by increasing demand for automated cell counting and analysis solutions in biotechnology and pharmaceutical industries, coupled with expansion into new geographic markets and strategic partnerships. Additionally, the company's focus on innovation and R&D has led to the development of new products and services, further contributing to the segment's growth.
Chemometec A/S Products
| Product Range | What is it ? |
|---|---|
| NucleoCounter | Automated cell counters for accurate and efficient cell counting |
| NucleoView | Advanced image analysis software for cell counting and characterization |
| Via2-Cassette | Disposable cassettes for cell counting and analysis |
| Via2-NC | Automated cell counters for high-throughput cell counting and analysis |
| NucleoChem | Automated cell counters for cell counting and analysis in chemical and biochemical applications |
ChemoMetec A/S's Porter Forces
Threat Of Substitutes
ChemoMetec A/S has a moderate threat of substitutes due to the availability of alternative products in the market.
Bargaining Power Of Customers
ChemoMetec A/S has a low bargaining power of customers due to the specialized nature of its products.
Bargaining Power Of Suppliers
ChemoMetec A/S has a moderate bargaining power of suppliers due to the availability of multiple suppliers in the market.
Threat Of New Entrants
ChemoMetec A/S has a high threat of new entrants due to the growing demand for cell counting and analysis solutions.
Intensity Of Rivalry
ChemoMetec A/S operates in a moderately competitive market with a few established players, leading to a medium intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.33% |
| Debt Cost | 10.25% |
| Equity Weight | 98.67% |
| Equity Cost | 10.25% |
| WACC | 10.25% |
| Leverage | 1.34% |
ChemoMetec A/S : Quality Control
ChemoMetec A/S passed 9 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| INMD | InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and … |
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| EUZ.DE | Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and … |
| GBT.PA | Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and … |
| ELN.MI | EL.En. S.p.A. engages in the research and development, manufacture, distribution, and sale of laser systems in Europe and internationally. The company offers medical laser equipment for use in the fields … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
EL.En
A-Score
1-Year Total Return ->
🥈
ChemoMetec
A-Score
1-Year Total Return ->
🥉
InMode
A-Score
1-Year Total Return ->
4
Guerbet
A-Score
1-Year Total Return ->
5
CellaVision
A-Score
1-Year Total Return ->
6
